Patients With Diabetes Have Comparable Health Expenses After RYGB or Sleeve Gastrectomy
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 28, 2025 -- For patients with diabetes undergoing Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG), overall expenditures decrease in the postsurgical period, with no differences seen following the first six months after surgery, according to a study published online Jan. 28 in the Annals of Internal Medicine.
Matthew L. Maciejewski, Ph.D., of Duke University in Durham, North Carolina, and colleagues compared health expenditures three years before and 5.5 years after bariatric surgery among patients with diabetes undergoing RYGB (3,147 patients) or SG (3,510 patients) from 2012 to 2019.
The researchers found that per six-month period, there was about a 30 percent decrease in expenditures for both groups, from $4,039.06 to $2,441.13 before and after RYGB and from $3,918.37 to $2,658.15 before and after SG. Through 5.5 years, there was no significant difference between the groups in total expenditures after surgery, except for the first six months, when expenditures were transiently higher in the RYGB group (difference, $564.32). This was driven by a higher rate of inpatient admission. Postsurgical outpatient and medication expenditures did not differ between the groups.
"These findings suggest that RYGB and SG do not substantially differ in reducing long-term health care costs for patients with type 2 diabetes," the authors write. "The substantial cost savings observed are primarily driven by reductions in medication expenditures, highlighting the economic benefits of bariatric surgery in managing diabetes."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
FRIDAY, May 23, 2025 -- Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in...
In Pediatric Leukemia, Survival Linked to Duration of Overweight, Obesity
TUESDAY, May 20, 2025 -- For children with acute lymphoblastic leukemia (ALL), longer duration of overweight or obesity is associated with lower overall and event-free survival...
GLP-1 Receptor Agonists Not Linked to Increased Risk of Psychiatric Adverse Events, Depression
MONDAY, May 19, 2025 -- For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.